Blog
Form 8.3 - The Vanguard Group, Inc.: THG plc
Form 8.3 - The Vanguard Group, Inc.: THG plc
Form 8.3 - The Vanguard Group, Inc.: Shaftesbury plc
Form 8.3 - The Vanguard Group, Inc.: Shaftesbury plc
Form 8.3 - The Vanguard Group, Inc.: NortonLife Lock Inc.
Form 8.3 - The Vanguard Group, Inc.: NortonLife Lock Inc.
Form 8.3 - The Vanguard Group, Inc.: Meggitt plc
Form 8.3 - The Vanguard Group, Inc.: Meggitt plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: FirstGroup plc
Form 8.3 - The Vanguard Group, Inc.: FirstGroup plc
Form 8.3 - The Vanguard Group, Inc.: Capital & Counties Properties plc
Form 8.3 - The Vanguard Group, Inc.: Capital & Counties Properties plc
Form 8.3 - The Vanguard Group, Inc.: Hibernian REIT plc
Form 8.3 - The Vanguard Group, Inc.: Hibernian REIT plc
Rights and Issues Investment Trust PLC: Net Asset Value(s)
Rights and Issues Investment Trust PLC: Net Asset Value(s)
EVRAZ plc publishes its report on payments to governments for 2021
EVRAZ plc publishes its report on payments to governments for 2021
Chelverton UK Dividend Trust plc: Net Asset Value(s)
Chelverton UK Dividend Trust plc: Net Asset Value(s)
DGAP-Adhoc: creditshelf Aktiengesellschaft:
DGAP-Adhoc: creditshelf Aktiengesellschaft:
Hardman & Co Research: Q&A on Oakley Capital Investments: Impressive market and peer-beating 19% NAV CAGR growth 2017-21
Hardman & Co Research: Q&A on Oakley Capital Investments: Impressive market and peer-beating 19% NAV CAGR growth 2017-21
DGAP-News: Cryptology’s estimated NAV per share as of 08/06/2022 is €6.45
DGAP-News: Cryptology’s estimated NAV per share as of 08/06/2022 is €6.45
DGAP-News: MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022
DGAP-News: MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022
Renewi plc: Annual Report and Accounts 2022 and Notice of Annual General Meeting
Renewi plc: Annual Report and Accounts 2022 and Notice of Annual General Meeting
Cairn Homes Plc: Transaction in Own Shares
Cairn Homes Plc: Transaction in Own Shares
Genel Energy PLC: Management change
Genel Energy PLC: Management change
Nordea Bank Abp: Transaction in Own Shares
Nordea Bank Abp: Transaction in Own Shares
HIAG Capital Market Day '22 on 27 September 2022
HIAG Capital Market Day '22 on 27 September 2022
DGAP-News: Biotest AG: Biotest achieves important milestone in Phase III study in acquired fibrinogen deficiency
DGAP-News: Biotest AG: Biotest achieves important milestone in Phase III study in acquired fibrinogen deficiency
Art Prize winner Anita Mucolli at LISTE 2022
Art Prize winner Anita Mucolli at LISTE 2022
Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
PJSC Magnitogorsk Iron and Steel Works: MMK notifies on extention of consent solicitation process
PJSC Magnitogorsk Iron and Steel Works: MMK notifies on extention of consent solicitation process
DGAP-Adhoc: Media and Games Invest successfully places EUR 175m of new senior secured bonds at 98.00% of par with a floating rate coupon of EURIBOR +6.25% and repurchases EUR 115m of existing senior secured bonds
DGAP-Adhoc: Media and Games Invest successfully places EUR 175m of new senior secured bonds at 98.00% of par with a floating rate coupon of EURIBOR +6.25% and repurchases EUR 115m of existing senior secured bonds


